A phase II study of alternate-day administration of S-1, oral leucovorin, oxaliplatin, and bevacizumab combination as first-line treatment in patients with metastatic colorectal cancer.
收藏NIAID Data Ecosystem2026-03-09 收录
官方服务：
资源简介：
Interventions: S-1 80-120 (mg/day) Monday, Wednesday, Friday, Sunday Leucovorin 50 (mg/day) Monday, Wednesday, Friday, Sunday Oxaliplatin 85 (mg/m2) day1 Bevacizumab 5 (mg/kg) day 1 every 2 weeks Primary outcome(s): Objective response rate as assessed by independent ragiologic review Study Design: Single arm Non-randomized
创建时间：
2016-01-15
